Literature DB >> 24329520

The prevalence of inverse recurrent suppuration: a population-based study of possible hidradenitis suppurativa.

G R Vinding1, I M Miller, K Zarchi, K S Ibler, C Ellervik, G B E Jemec.   

Abstract

BACKGROUND: Hidradenitis suppurativa (HS) is a chronic inflammatory disease involving inverse recurrent suppuration (IRS). The epidemiology of the disease is not well described, with previous studies reporting prevalence estimates from 0·00033% to 4%.
OBJECTIVE: To determine the prevalence of IRS in a large population-based survey.
METHODS: Data were obtained from a general cross-sectional population study in Denmark. A validated self-administered questionnaire was used to identify IRS. Persons with the combination of outbreaks of 'boils' during the last 6 months in predefined areas and a minimum of two boils were identified.
RESULTS: A total of 16 404 adults aged 30-89 years provided data and the overall prevalence of IRS was found to be 2·10% [95% confidence interval (CI) 1·88-2·32]; in men it was 1·58% (95% CI 1·29-1·86) and in women 2·56% (95% CI 2·21-2·86). No data for adults aged 20-29 years were included. The prevalence declined with age. The majority of cases (72·9%) had a body mass index of ≥ 25 kg m(-2) and 77·7% were current or ex-smokers. The mean number of inflamed lesions was 6·5 (range 2-67) during the last 6 months. The lesions affected mostly the genitalia (43·4%) and groin (39·8%) for women and 'other places' (not specified) (78·8%) for men.
CONCLUSIONS: Data on IRS suggest that HS may be more prevalent than previously suggested, and the prevalence may be comparable to other major dermatoses, e.g. psoriasis. However, as no physician examination was done, the risk of recall and information bias is a major limitation.
© 2013 British Association of Dermatologists.

Entities:  

Mesh:

Year:  2014        PMID: 24329520     DOI: 10.1111/bjd.12787

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  21 in total

1.  Clinical characteristics of pediatric hidradenitis suppurativa: a cross-sectional multicenter study of 140 patients.

Authors:  Peter Theut Riis; Ditte Marie Saunte; Viktoria Sigsgaard; Axel Patrice Villani; Philippe Guillem; José C Pascual; Naomi N Kappe; Annika M J D Vanlaerhoven; Hessel H van der Zee; Errol P Prens; Moetaz El-Domyati; Hossam Abdel-Wahab; Nayera Moftah; Rania Abdelghani; Eugenia Agut-Busquet; Jorge Romaní; Carol Hlela; Lerinza van den Worm; Vincenzo Bettoli; Giada Calamo; Mehmet Ali Gürer; Burcu Beksaç; Lukasz Matusiak; Amelia Glowaczewska; Jacek C Szepietowski; Lennart Emtestam; Jan Lapins; Hassan Riad Kottb; Mohammad Fatani; Lisa Weibel; Martin Theiler; Maïa Delage-Toriel; Thi Thanh Hong Lam; Aude Nassif; Pierre-Andre Becherel; Mateja Dolenc-Voljc; Nejib Doss; Dorra Bouazzi; Farida Benhadou; Veronique Del Marmol; Gregor B E Jemec
Journal:  Arch Dermatol Res       Date:  2020-03-12       Impact factor: 3.017

2.  The Follicular Skin Microbiome in Patients With Hidradenitis Suppurativa and Healthy Controls.

Authors:  Hans Christian Ring; Jonathan Thorsen; Ditte M Saunte; Berit Lilje; Lene Bay; Peter Theut Riis; Niels Larsen; Lee O'Brien Andersen; Henrik V Nielsen; Iben M Miller; Thomas Bjarnsholt; Kurt Fuursted; Gregor Borut Jemec
Journal:  JAMA Dermatol       Date:  2017-09-01       Impact factor: 10.282

3.  Sex- and Age-Adjusted Population Analysis of Prevalence Estimates for Hidradenitis Suppurativa in the United States.

Authors:  Amit Garg; Joslyn S Kirby; Jonathan Lavian; Gloria Lin; Andrew Strunk
Journal:  JAMA Dermatol       Date:  2017-08-01       Impact factor: 10.282

Review 4.  Hidradenitis suppurativa in children and adolescents: a review of treatment options.

Authors:  Peter Riis Mikkelsen; Gregor B E Jemec
Journal:  Paediatr Drugs       Date:  2014-12       Impact factor: 3.022

5.  Overall and Subgroup Prevalence of Crohn Disease Among Patients With Hidradenitis Suppurativa: A Population-Based Analysis in the United States.

Authors:  Amit Garg; Jessica Hundal; Andrew Strunk
Journal:  JAMA Dermatol       Date:  2018-07-01       Impact factor: 10.282

Review 6.  Pain, Psychological Comorbidities, Disability, and Impaired Quality of Life in Hidradenitis Suppurativa [corrected].

Authors:  Zarine S Patel; Lauren K Hoffman; Dawn C Buse; Amy S Grinberg; Ladan Afifi; Steven R Cohen; Michelle A Lowes; Elizabeth K Seng
Journal:  Curr Pain Headache Rep       Date:  2017-11-01

Review 7.  Botulinum toxin type A for the management of hidradenitis suppurativa.

Authors:  Huanhuan Qu; Lin Gao
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

8.  Posterior Arm Perforator Flap for Axillary Reconstruction After Hidradenitis Suppurativa Excision.

Authors:  Selami Serhat Sirvan; Isil Akgun Demir; Fatih Irmak; Kamuran Zeynep Sevim; Daghan Dagdelen; Sevgi Kurt Yazar; Semra Karsidag
Journal:  Plast Surg (Oakv)       Date:  2019-02-21       Impact factor: 0.947

9.  Dynamic Leukocyte Populations Are Associated With Early- and Late-stage Lesions in Hidradenitis Suppurativa.

Authors:  Savanna R Altman; Sheila L Criswell
Journal:  J Histochem Cytochem       Date:  2020-11-26       Impact factor: 2.479

10.  A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process.

Authors:  L Thorlacius; J R Ingram; B Villumsen; S Esmann; J S Kirby; A B Gottlieb; J F Merola; R Dellavalle; S M Nielsen; R Christensen; A Garg; G B E Jemec
Journal:  Br J Dermatol       Date:  2018-07-05       Impact factor: 11.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.